Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

TCRT

Alaunos Therapeutics Inc

Dec 24 • 01:30PM ET

1.96

Dollar change +0.01
Percentage change 0.49	%

Healthcare • Biotechnology • USA • NASD

Peers: MRNA NTLA EDIT BEAM PGEN KPTI FATE ADAP SGMO IMTX

| Held by: VXF

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.36	Insider Own	14.04%	Shs Outstand	1.60M	Perf Week	-5.32%
Market Cap	3.21M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	1.38M	Perf Month	-18.00%
Income	-11.78M	PEG	-	EPS next Q	-	Inst Own	11.99%	Short Float	9.65%	Perf Quarter	-50.26%
Sales	0.01M	P/S	320.53	EPS this Y	-	Inst Trans	-25.73%	Short Ratio	5.77	Perf Half Y	-70.03%
Book/sh	1.70	P/B	1.15	EPS next Y	-	ROA	-102.49%	Short Interest	0.13M	Perf Year	-73.60%
Cash/sh	1.03	P/C	1.91	EPS next 5Y	-	ROE	-141.73%	52W Range	1.63 - 32.85	Perf YTD	-81.52%
Dividend Est.	-	P/FCF	-	EPS past 5Y	21.41%	ROI	-432.49%	52W High	-94.03%	Beta	-0.43
Dividend TTM	-	Quick Ratio	4.30	Sales past 5Y	86.87%	Gross Margin	-3966.67%	52W Low	20.24%	ATR (14)	0.24
Dividend Ex-Date	-	Current Ratio	4.30	EPS Y/Y TTM	68.32%	Oper. Margin	-123633.33%	RSI (14)	44.47	Volatility	7.08% 13.00%
Employees	1	Debt/Eq	0.00	Sales Y/Y TTM	-60.00%	Profit Margin	-196350.00%	Recom	3.00	Target Price	1125.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	86.71%	Payout	-	Rel Volume	0.21	Prev Close	1.95
Sales Surprise	-	EPS Surprise	-14.29%	Sales Q/Q	-	Earnings	-	Avg Volume	23.08K	Price	1.96
SMA20	-9.50%	SMA50	-9.99%	SMA200	-70.93%	Trades		Volume	5,028	Change	0.49%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-04-22	Resumed	Wells Fargo	Overweight	$3

Oct-11-24 08:57AM	Alaunos Therapeutics Ends Licensing Deal, Reassesses Strategy (TipRanks)
May-15-24 10:55PM	TCRT Stock Earnings: Alaunos Therapeutics Reported Results for Q1 2024 (InvestorPlace) -7.39%
Apr-08-24 12:52PM	TCRT Stock Earnings: Alaunos Therapeutics Misses EPS for Q4 2023 (InvestorPlace)
Dec-18-23 07:57AM	Why Is Alaunos Therapeutics (TCRT) Stock Up 37% Today? (InvestorPlace) +26.15%
Nov-14-23 07:56AM	Why Is Alaunos Therapeutics (TCRT) Stock Up 14% Today? (InvestorPlace) -10.59%
07:30AM	Loading…
07:30AM	Alaunos Therapeutics Announces Third Quarter 2023 Financial Results, Phase 1 Clinical Data and Continued Exploration of Strategic Alternatives (GlobeNewswire)
Aug-14-23 04:05PM	Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim Clinical Data and Exploration of Strategic Alternatives (GlobeNewswire) -64.68%
Jun-29-23 07:00AM	Alaunos Therapeutics Announces Presentation at the 2nd Hawaii Global Summit on Thoracic Malignancies (GlobeNewswire) +14.30%
May-25-23 05:00PM	Alaunos Therapeutics to Present Early Data from TCR-T Library Phase 1/2 Trial at 2023 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -16.65%
May-10-23 07:00AM	Alaunos Therapeutics Reports First Quarter 2023 Financial Results (GlobeNewswire)
May-03-23 08:30AM	Alaunos Therapeutics to Report First Quarter 2023 Financial Results on May 10, 2023 (GlobeNewswire)
Apr-26-23 12:30PM	Alaunos Therapeutics Announces Poster Presentation at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting (GlobeNewswire) +6.57%
Mar-30-23 07:00AM	Alaunos Therapeutics Appoints Dr. Robert J. Hofmeister to Board of Directors (GlobeNewswire)
Mar-29-23 05:30PM	Alaunos Therapeutics to Participate in Upcoming Investor Conferences in April (GlobeNewswire) +6.72%
Mar-07-23 07:00AM	Alaunos Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results (GlobeNewswire)
04:01PM	Loading…
Feb-28-23 04:01PM	Alaunos Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on March 7, 2023 (GlobeNewswire)
Feb-17-23 05:47AM	Alaunos Therapeutics, Inc.'s (NASDAQ:TCRT) largest shareholders are individual investors with 58% ownership, institutions own 22% (Simply Wall St.)
Jan-09-23 08:30AM	Alaunos Therapeutics Highlights Strategic Priorities and Anticipated Portfolio Milestones for 2023 (GlobeNewswire)
Nov-29-22 09:01AM	Alaunos Therapeutics Announces Pricing of Public Offering of Common Stock (GlobeNewswire) -22.78%
Nov-28-22 04:01PM	Alaunos Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) -5.84%
Nov-14-22 07:00AM	Alaunos Therapeutics Reports Third Quarter 2022 Financial Results (GlobeNewswire) -6.48%
Nov-08-22 08:30AM	Alaunos Therapeutics to Report Third Quarter 2022 Financial Results on November 14, 2022 (GlobeNewswire)
Nov-07-22 08:00AM	Alaunos Therapeutics to Present Data Highlighting its hunTR TCR Discovery Platform at the Society for Immunotherapy of Cancer 2022 Annual Meeting (GlobeNewswire)
Sep-21-22 08:30AM	Alaunos Therapeutics Highlights Data from TCR-T Library Phase 1/2 Trial at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (GlobeNewswire) -20.87%
Sep-07-22 08:30AM	Alaunos Therapeutics to Participate in Upcoming Investor Conferences in September (GlobeNewswire) +18.21%
Sep-06-22 08:00AM	Alaunos Therapeutics Announces Early Clinical Data Showing Objective Clinical Response Using its TCR-T Cell Therapy (GlobeNewswire)
Aug-24-22 03:00PM	Alaunos Therapeutics to Present at the CRI-ENCI-AACR Sixth International Cancer Immunotherapy Conference (GlobeNewswire) +20.00%
Aug-15-22 07:00AM	Alaunos Therapeutics Reports Second Quarter 2022 Financial Results (GlobeNewswire) +18.18%
Aug-08-22 08:50AM	Alaunos Therapeutics to Report Second Quarter 2022 Financial Results on August 15, 2022 (GlobeNewswire)
Aug-04-22 05:00PM	Alaunos Therapeutics Appoints Abhishek Srivastava, Ph.D. as Vice President, Technical Operations (GlobeNewswire) +8.39%
09:31AM	Loading…
Jul-06-22 09:31AM	Thinking about buying stock in Verrica Pharmaceuticals, Scisparc, Adverum Biotechnologies, OneConnect Financial Tech, or Alaunos Therapeutics? (PR Newswire) +13.45%
Jun-30-22 07:07AM	Is Alaunos Therapeutics (NASDAQ:TCRT) Using Debt In A Risky Way? (Simply Wall St.)
Jun-27-22 08:00AM	Alaunos Therapeutics and the National Cancer Institute Extend Cooperative Research and Development Agreement for Development of Personalized TCR-T Cell Therapies to 2025 (GlobeNewswire) +17.27%
Jun-01-22 08:30AM	Alaunos Therapeutics to Present at the Jefferies Healthcare Conference (GlobeNewswire) -8.63%
May-26-22 05:01PM	Alaunos Therapeutics to Present Trials in Progress Poster for its TCR-T Library Phase 1/2 trial at the 2022 American Society of Clinical Oncology Annual Meeting (GlobeNewswire) +11.09%
May-16-22 07:30AM	Alaunos Therapeutics Reports First Quarter 2022 Financial Results (GlobeNewswire) -15.15%
May-12-22 11:48AM	Insiders who placed huge bets on Alaunos Therapeutics, Inc. (NASDAQ:TCRT) earlier this year would be disappointed with the 27% drop (Simply Wall St.) +5.89%
May-10-22 08:30AM	Alaunos Therapeutics to Present at the H.C. Wainwright Global Investment Conference (GlobeNewswire) +6.16%
May-09-22 08:30AM	Alaunos Therapeutics to Report First Quarter 2022 Financial Results on May 16, 2022 (GlobeNewswire)
May-02-22 04:31PM	Alaunos Therapeutics to Present at American Society of Gene and Cell Therapy 25th Annual Meeting (GlobeNewswire) -7.28% +12.66%
08:30AM	Alaunos Therapeutics Doses First Patient in TCR-T Library Phase 1/2 trial for the Treatment of Patients with Solid Tumors (GlobeNewswire)
Mar-30-22 07:30AM	Alaunos Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results (GlobeNewswire)
Mar-22-22 01:58PM	What Percentage Of Alaunos Therapeutics, Inc. (NASDAQ:TCRT) Shares Do Insiders Own? (Simply Wall St.)
Mar-16-22 08:30AM	Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022 (GlobeNewswire) +8.41%
Mar-08-22 04:05PM	Alaunos Therapeutics to Participate in the Oppenheimer 32nd Annual Healthcare Conference (GlobeNewswire) +21.63%

Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TCRT

Alaunos Therapeutics Inc

Upgrade your FINVIZ experience